Menu

Caught on Camera

Selected Images of the Day from the-scientist.com

Apr 1, 2018
The Scientist Staff

ASSASSIN FOR HIRE: Researchers in Switzerland have made progress in designing non-immune cells that can target and attack tumor cells, as shown in this artist's depiction.
Posted: November 13, 2017
RYO TACHIBANA
ROBODOCS: Researchers use DNA origami to generate tiny mechanical devices that deliver a drug that cuts off the blood supply to tumors in mice.
Posted: February 12, 2018
BAOQUAN DING AND HAO YAN
FISH AVATARS FOR CANCER: Zebrafish larvae transplanted with patients’ tumors (red) respond as their human donors do to chemotherapy.
Posted: September 11, 2017
RITA FIOR, CHAMPALIMAUD CENTRE FOR THE UNKNOWN

 

MANIPULATIVE MELANOMAS: Early-stage melanoma cells (gray) alter proteins in nearby skin cells (red) to create a favorable environment for cancer progression.
Posted: March 20, 2017
DEPARTMENT OF DERMATOLOGY, UNIVERSITY HOSPITAL ERLANGEN, TRANSLATIONSAL RESEARCH CENTER, GERMANY

 

SUNBURN: Melanoma (red and black on the left and right, respectively) in mouse melanocyte stem cells
Posted: October 20, 2017
HYEONGSUN MOON AND ANDREW WHITE, CORNELL UNIVERSITY
CANCER’S CRYSTAL BALLS: Testing treatments on mini tumors, such as these gastroesophageal cancer organoids, may save time in identifying which therapies work best.
Posted: February 22, 2018
GEORGE VLACHOGIANNIS

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.